How New Data From ASCO 2024 Will Affect Prostate Cancer Care

Sandy Srinivas, MD

June 25, 2024

Returning from ASCO 2024, Sandy Srinivas, MD, discusses the results from the PSMAfore trial, which compared lutetium-177(¹⁷⁷Lu)-PSMA-617 with alternate androgen receptor pathway inhibitors [ARPIs] in patients with metastatic castration-resistant prostate cancer. The trial showed that ¹⁷⁷Lu-PSMA-617 significantly improved radiographic progression-free survival, doubling it from 5.5 months with alternate ARPIs to 12 months.

Additionally, quality-of-life data indicated a substantial improvement for patients receiving ¹⁷⁷Lu-PSMA-617. Although overall survival results were affected by a large crossover, a favorable hazard ratio was suggested in a press release. Dr Srinivas describes the potential benefits of this new treatment option for patients who are too frail for chemotherapy.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: How New Data From ASCO 2024 Will Affect Prostate Cancer Care - Medscape - Jun 25, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

How New Data From ASCO 2024 Will Affect Prostate Cancer Care

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Sandy Srinivas, MD

Comments

Email This

Feedback